Retatrutide

What is Retatrutide?

Retatrutide (LY-3437943) is an experimental synthetic peptide and a triple glucagon hormone receptor agonist, targeting the GLP-1, GIP, and glucagon (GCGR) receptors simultaneously. It is structurally engineered with a fatty diacid moiety, resulting in an extended half-life of approximately six days Patsnap Synapse — making it suitable for once-weekly administration in research settings.

Mechanism of Action

Retatrutide acts as an agonist of GLP-1, GIP, and glucagon receptors through a single continuous helical structure that interacts with the receptor’s transmembrane domain. It is more potent at the human GIP receptor and less potent at the GLP-1 and glucagon receptors. PubMed Central This triagonism mediates an integrated response where increased cAMP production drives improved insulin secretion and metabolic regulation, while also modulating appetite and energy expenditure. Patsnap Synapse Unlike single or dual agonists, the addition of glucagon receptor agonism leads to increased energy expenditure — a unique mechanism not seen with GLP-1 agonists alone. PubMed Central

Areas of Research

• Weight & Body Composition: Systematic reviews of randomized controlled trials report that retatrutide produces mean body weight reductions of 15–24% over 48 to 72 weeks, depending on study protocols and populations. Wikipedia
• Glycemic Control: Studies have shown significant reductions in fasting plasma glucose (mean –23.51 mg/dL) and HbA1c (mean –0.91%) across multiple randomized controlled trials. PubMed Central
• Liver Fat (MASLD/NAFLD): A Phase 2a trial published in Nature Medicine showed retatrutide produced up to 82% reduction in liver fat, with most of the reduction occurring within the first 24 weeks. Nature
• Cardiometabolic Markers: Beyond weight and glycemic control, retatrutide shows promise in mitigating cardiovascular risk factors, improving lipid profiles, and addressing metabolic dysfunction-associated steatotic liver disease. ScienceDirect
• Energy Expenditure: Glucagon receptor activation increases metabolic rate and energy expenditure, which has potential implications for modifying cardiovascular risk factors and overall metabolic health. Patsnap Synapse

Reconstitution & Handling (Research Use)

Retatrutide is supplied in lyophilized (freeze-dried) form. For laboratory research, it is typically reconstituted using bacteriostatic water. Once reconstituted, store refrigerated between 36–46°F (2–8°C) and use within the recommended stability window. Prior to reconstitution, store at -4°F (-20°C), away from light and moisture.

Scientific References

• Jastreboff AM, et al. New England Journal of Medicine. 2023. (Phase 2 Trial — NCT04881760)
• Rosenstock J, et al. The Lancet. 2023; 402:529–544.
• Nature Medicine. 2024 — Phase 2a MASLD Trial
• PubMed: PMC12190491 | PMC12026077 | PMC11486854